User profiles for Arber Shehu
 | Arber ShehuJohns Hopkins University Verified email at jh.edu Cited by 3014 |
Effectiveness of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccines for preventing coronavirus disease 2019 hospitalizations in the United …
Background As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
vaccination coverage increases in the United States, there is a need to understand the real-world …
vaccination coverage increases in the United States, there is a need to understand the real-world …
Association between mRNA vaccination and COVID-19 hospitalization and disease severity
Importance A comprehensive understanding of the benefits of COVID-19 vaccination requires
consideration of disease attenuation, determined as whether people who develop COVID-…
consideration of disease attenuation, determined as whether people who develop COVID-…
Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective …
Objectives To characterize the clinical severity of covid-19 associated with the alpha, delta,
and omicron SARS-CoV-2 variants among adults admitted to hospital and to compare the …
and omicron SARS-CoV-2 variants among adults admitted to hospital and to compare the …
[HTML][HTML] Effectiveness of SARS-CoV-2 mRNA vaccines for preventing Covid-19 hospitalizations in the United States
Background: As SARS-CoV-2 vaccination coverage increases in the United States (US), there
is a need to understand the real-world effectiveness against severe Covid-19 and among …
is a need to understand the real-world effectiveness against severe Covid-19 and among …
[HTML][HTML] Clinical severity and mRNA vaccine effectiveness for omicron, delta, and alpha SARS-CoV-2 variants in the United States: a prospective observational study
Objectives To characterize the clinical severity of COVID-19 caused by Omicron, Delta, and
Alpha SARS-CoV-2 variants among hospitalized adults and to compare the effectiveness of …
Alpha SARS-CoV-2 variants among hospitalized adults and to compare the effectiveness of …
mRNA vaccine effectiveness against coronavirus disease 2019 hospitalization among solid organ transplant recipients
Background The study objective was to evaluate 2- and 3-dose coronavirus disease 2019 (COVID-19)
mRNA vaccine effectiveness (VE) in preventing COVID-19 hospitalization among …
mRNA vaccine effectiveness (VE) in preventing COVID-19 hospitalization among …
Effectiveness of mRNA vaccines against COVID-19 hospitalization by age and chronic medical conditions burden among immunocompetent US adults, March-August …
Vaccine effectiveness (VE) against COVID-19 hospitalization was evaluated among
immunocompetent adults (≥18 years) during March–August 2021 using a case-control design. …
immunocompetent adults (≥18 years) during March–August 2021 using a case-control design. …
Comparison of test-negative and syndrome-negative controls in SARS-CoV-2 vaccine effectiveness evaluations for preventing COVID-19 hospitalizations in the …
Background Test-negative design (TND) studies have produced validated estimates of vaccine
effectiveness (VE) for influenza vaccine studies. However, syndrome-negative controls …
effectiveness (VE) for influenza vaccine studies. However, syndrome-negative controls …
Effectiveness of the Ad26. COV2. S (Johnson & Johnson) coronavirus disease 2019 (COVID-19) vaccine for preventing COVID-19 hospitalizations and progression to …
Background . Adults in the United States (US) began receiving the adenovirus vector coronavirus
disease 2019 (COVID-19) vaccine, Ad26.COV2.S (Johnson & Johnson [Janssen]), in …
disease 2019 (COVID-19) vaccine, Ad26.COV2.S (Johnson & Johnson [Janssen]), in …
Protection of mRNA vaccines against hospitalized COVID-19 in adults over the first year following authorization in the United States
BackgroundCoronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccines
were authorized in the United States in December 2020. Although vaccine effectiveness (VE) …
were authorized in the United States in December 2020. Although vaccine effectiveness (VE) …
